Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Feb;38(2):197-206.
doi: 10.1007/s40264-014-0262-8.

Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support

Richard T Scheife  1 , Lisa E Hines, Richard D Boyce, Sophie P Chung, Jeremiah D Momper, Christine D Sommer, Darrell R Abernethy, John R Horn, Stephen J Sklar, Samantha K Wong, Gretchen Jones, Mary L Brown, Amy J Grizzle, Susan Comes, Tricia Lee Wilkins, Clarissa Borst, Michael A Wittie, Daniel C Malone
Affiliations

Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support

Richard T Scheife et al. Drug Saf. 2015 Feb.

Abstract

Background: Healthcare organizations, compendia, and drug knowledgebase vendors use varying methods to evaluate and synthesize evidence on drug-drug interactions (DDIs). This situation has a negative effect on electronic prescribing and medication information systems that warn clinicians of potentially harmful medication combinations.

Objective: The aim of this study was to provide recommendations for systematic evaluation of evidence for DDIs from the scientific literature, drug product labeling, and regulatory documents.

Methods: A conference series was conducted to develop a structured process to improve the quality of DDI alerting systems. Three expert workgroups were assembled to address the goals of the conference. The Evidence Workgroup consisted of 18 individuals with expertise in pharmacology, drug information, biomedical informatics, and clinical decision support. Workgroup members met via webinar 12 times from January 2013 to February 2014. Two in-person meetings were conducted in May and September 2013 to reach consensus on recommendations.

Results: We developed expert consensus answers to the following three key questions. (i) What is the best approach to evaluate DDI evidence? (ii) What evidence is required for a DDI to be applicable to an entire class of drugs? (iii) How should a structured evaluation process be vetted and validated?

Conclusion: Evidence-based decision support for DDIs requires consistent application of transparent and systematic methods to evaluate the evidence. Drug compendia and clinical decision support systems in which these recommendations are implemented should be able to provide higher-quality information about DDIs.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Conceptual Model for Evaluating Drug-Drug Interactions to Guide Clinical Decision-Making
See this image and copyright information in PMC

References

    1. Aspden P, Institute of Medicine (U.S.). Committee on Identifying and Preventing Medication Errors. Preventing medication errors. Washington, DC: National Academies Press; 2007.
    1. Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. Expert Opin Drug Saf. 2012 Jan;11(1):83–94. - PubMed
    1. CDC. FASTSTATS - Emergency Department Visits. 2012 [cited 12/06/2013]; Available from: http://www.cdc.gov/nchs/fastats/ervisits.htm.
    1. CDC. FASTSTATS - Hospital Utilization. 2010 [cited 12/06/2013]; Available from: http://www.cdc.gov/nchs/fastats/hospital.htm.
    1. CMS. Eligible Professional Meaningful Use Core Measures: Measure 2 of 15. Centers for Medicare and Medicaid Services; 2010. [cited 01/09/2013]; Available from: http://www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentiveProg....

Publication types

MeSH terms